1. Maridebart cafraglutide shows significant weight loss (12.3% to 16.2%).
2. Participants were treated over 52 weeks at multiple international sites.
3. Improvements in glycemic control were noted in diabetes participants.
4. Majority of weight loss derived from fat mass reduction.
5. Mild to moderate adverse events primarily gastrointestinal.
6. Half-life of maridebart cafraglutide is 21 days, allowing for less frequent dosing.
7. Ongoing studies to assess long-term weight maintenance strategies.

Source: The New England Journal of Medicine